Lipitor May Not Prevent Cardiac Events in Patients With Type 2 Diabetes Receiving Hemodialysis

Atorvastatin (Lipitor) does not improve overall outcome for patients with type 2 diabetes mellitus (DM) requiring Hemodialysis, according to the results of a multicenter, randomized study published in the July 21 issue of the New England Journal of Medicine. The investigators speculate that this may be too late in the disease course for therapy to be beneficial.

"Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus," write Christoph Wanner, MD, from the University of Wurzburg in Germany, and colleagues. "However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined."

In this double-blind, prospective study, 1,255 patients with type 2 diabetes receiving maintenance hemodialysis were randomized to receive 20 mg of atorvastatin per day or matching placebo.

The primary outcome measure was a composite of death from cardiac causes, nonfatal Myocardial Infarction (MI), and stroke; and secondary outcomes included death from all causes and all cardiac and cerebrovascular events combined. Median duration of follow-up was four years.

After four weeks of treatment, the median level of low-density lipoprotein (LDL) cholesterol decreased by 42% in the atorvastatin group and by 1.3% in the placebo group. During follow-up, 469 patients (37%) reached the primary endpoint: 226 in the atorvastatin group and 243 in the placebo group (relative risk [RR], 0.92; 95% confidence interval [CI], 0.77 - 1.10; P = .37).

The RR for fatal stroke in the atorvastatin group was 2.03 (95% CI, 1.05 - 3.93; P = .04); otherwise, atorvastatin did not significantly affect the individual components of the primary endpoint. Although atorvastatin was associated with lower RR of all cardiac events combined (0.82; 95% CI, 0.68 - 0.99; P = .03), it did not significantly affect all cerebrovascular events combined (RR, 1.12; 95% CI, 0.81 - 1.55; P = .49) or total mortality (RR, 0.93; 95% CI, 0.79 - 1.08; P = .33).

"Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis," the authors write. "Of nominal significance, more cases of fatal stroke occurred in the atorvastatin group (27) than in the placebo group (13). This finding is unexplained and could be a chance finding, particularly in view of the data from CARDS [the Collaborative Atorvastatin Diabetes Study], which indicate that lowers the incidence of ."